GEVA undervalued but retail guys don't understand orphan drug companies
unbelievable how this message board is inactive. one of the most high profile companies for institutional investors in the biotech sector and not one person enthusiastically talking about upcoming data in Q3:14.
Maybe you can give more of an explanation. On hedge fund holds 33% of GEVA. So there is not a lot of institutional investors. Also when I did a little research I thought I read the current drug / protein they are working treats people with a rare disease. Thus they will not have very many potential customers.
Geva is a high priced stock (not trading under $10) and is not a microcap or smallcap biotech stock seems like it doesnt get the interest of retail traders. I found this company by researching baker bros top holdings and this was one of them. What are other orphan drug companies that you are interested in?